ATE140265T1 - Probiotik - Google Patents

Probiotik

Info

Publication number
ATE140265T1
ATE140265T1 AT92303007T AT92303007T ATE140265T1 AT E140265 T1 ATE140265 T1 AT E140265T1 AT 92303007 T AT92303007 T AT 92303007T AT 92303007 T AT92303007 T AT 92303007T AT E140265 T1 ATE140265 T1 AT E140265T1
Authority
AT
Austria
Prior art keywords
novel strain
probiotics
human
ncimb
deposited
Prior art date
Application number
AT92303007T
Other languages
English (en)
Inventor
William Dennis Allen
House
Margaret Anneli Linggod
House Colworth
Philip Porter
Original Assignee
Quest Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quest Int filed Critical Quest Int
Application granted granted Critical
Publication of ATE140265T1 publication Critical patent/ATE140265T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; PREPARATION THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/1203—Addition of, or treatment with, enzymes or microorganisms other than lactobacteriaceae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; PREPARATION THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
    • A23C9/1236—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt using Leuconostoc, Pediococcus or Streptococcus sp. other than Streptococcus Thermophilus; Artificial sour buttermilk in general
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; PREPARATION THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/127—Fermented milk preparations; Treatment using microorganisms or enzymes using microorganisms of the genus lactobacteriaceae and other microorganisms or enzymes, e.g. kefir, koumiss
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS OR COOKING OILS
    • A23D7/00—Edible oil or fat compositions containing an aqueous phase, e.g. margarines
    • A23D7/005—Edible oil or fat compositions containing an aqueous phase, e.g. margarines characterised by ingredients other than fatty acid triglycerides
    • A23D7/0056—Spread compositions
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/21—Streptococcus, lactococcus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/46—Streptococcus ; Enterococcus; Lactococcus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Jellies, Jams, And Syrups (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Seasonings (AREA)
  • Fodder In General (AREA)
  • Dairy Products (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT92303007T 1991-04-08 1992-04-06 Probiotik ATE140265T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB919107305A GB9107305D0 (en) 1991-04-08 1991-04-08 Probiotic

Publications (1)

Publication Number Publication Date
ATE140265T1 true ATE140265T1 (de) 1996-07-15

Family

ID=10692798

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92303007T ATE140265T1 (de) 1991-04-08 1992-04-06 Probiotik

Country Status (14)

Country Link
US (2) US5589168A (de)
EP (1) EP0508701B1 (de)
JP (1) JP3186202B2 (de)
KR (1) KR0123456B1 (de)
AT (1) ATE140265T1 (de)
AU (1) AU652815B2 (de)
CA (1) CA2064954A1 (de)
DE (1) DE69212034T2 (de)
DK (1) DK0508701T3 (de)
ES (1) ES2089398T3 (de)
GB (1) GB9107305D0 (de)
GR (1) GR3021069T3 (de)
IE (1) IE921092A1 (de)
NZ (1) NZ242195A (de)

Families Citing this family (141)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6562629B1 (en) * 1999-08-11 2003-05-13 Cedars-Sinai Medical Center Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth by detecting the presence of anti-saccharomyces cerivisiae antibodies (asca) in human serum
US6861053B1 (en) * 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US5630410A (en) * 1996-01-04 1997-05-20 Us Navy Accelerated gas removal from divers' tissues utilizing gas metabolizing bacteria
AU6838996A (en) * 1996-05-27 1998-01-05 Alexei Nikolaevich Parfenov Use of streptococcus faecium strains and composition containing the same
US6583275B1 (en) 1997-07-02 2003-06-24 Genome Therapeutics Corporation Nucleic acid sequences and expression system relating to Enterococcus faecium for diagnostics and therapeutics
US8563522B2 (en) 1997-07-08 2013-10-22 The Iams Company Method of maintaining and/or attenuating a decline in quality of life
US5965128A (en) * 1997-08-13 1999-10-12 University Of Georgia Research Foundation Inc. Control of enterohemorrhagic E. coli 0157:H7 in cattle by probiotic bacteria and specific strains of E. coli
US5879719A (en) * 1997-08-28 1999-03-09 Midwest Zoological Research, Inc. Process for control, elimination or inhibition of salmonellae in reptiles and/or amphibians
IT1298918B1 (it) * 1998-02-20 2000-02-07 Mendes Srl Uso di batteri dotati di arginina deiminasi per indurre apoptosi e/o ridurre una reazione infiammatoria e composizioni farmaceutiche
ID29150A (id) 1999-01-15 2001-08-02 Entpr Ireland Cs Penggunaan lactobacillus salivarius
US6283294B1 (en) * 1999-09-01 2001-09-04 Biogaia Biologics Ab Enclosed living cell dispensing tube
US20040047868A1 (en) * 2000-07-03 2004-03-11 Gerald Pang Treating endotoxemia and related disorders with probiotics
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
FR2814913B1 (fr) * 2000-10-11 2005-06-03 Amora Maille Emulsion comestible comprenant des micro-organismes vivants et vinaigrette ou sauce d'accompagnement comprenant ladite emulsion comestible
US6517832B1 (en) * 2001-08-24 2003-02-11 Jeffrey L. Marrongelle Formulations and methods for treating chronic migraine
NZ515881A (en) * 2001-12-03 2004-09-24 New Zealand Dairy Board Cheese flavour ingredient and method of its production
RU2220199C1 (ru) * 2002-07-03 2003-12-27 Алехина Галина Геннадьевна Штамм энтерококков enterococcus faecium l-3 для изготовления лечебно-профилактических средств и продуктов питания лечебно-профилактического назначения
US20040197304A1 (en) 2003-04-01 2004-10-07 The Procter & Gamble Company And Alimentary Health, Ltd. Methods of determining efficacy of treatments of inflammatory diseases of the bowel
AU2004265511A1 (en) * 2003-08-18 2005-02-24 The Bio Balance Corporation A stable liquid probiotic composition, preparation and applications thereof
US8192733B2 (en) 2003-08-29 2012-06-05 Cobb & Associates Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions
US7759105B2 (en) * 2003-08-29 2010-07-20 Cobb & Company, Llp Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions
US7731976B2 (en) 2003-08-29 2010-06-08 Cobb And Company, Llp Treatment of irritable bowel syndrome using probiotic composition
US7749509B2 (en) 2003-08-29 2010-07-06 Cobb And Company, Llp Treatment of autism using probiotic composition
US20070009490A1 (en) * 2003-10-02 2007-01-11 Conte Anthony E Dried biotherapeutic composition, uses, and device and methods for administration thereof
KR20060109452A (ko) * 2003-10-02 2006-10-20 더 바이오 밸런스 코포레이션 건조 바이오치료 조성물, 용도, 그 투여 장치 및 투여 방법
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US7785635B1 (en) 2003-12-19 2010-08-31 The Procter & Gamble Company Methods of use of probiotic lactobacilli for companion animals
US20050152884A1 (en) 2003-12-19 2005-07-14 The Procter & Gamble Company Canine probiotic Bifidobacteria globosum
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
US8894991B2 (en) 2003-12-19 2014-11-25 The Iams Company Canine probiotic Lactobacilli
MY143693A (en) 2004-03-24 2011-06-30 Nestec Sa Shelf stable product wih living micro-organisms
NO20050044L (no) * 2005-01-04 2006-07-05 Innovest As Preparat for behandling av Colitis ulcerosa & Chrohn's sykdom
JP4938006B2 (ja) 2005-05-31 2012-05-23 ザ・アイムス・カンパニー ネコ科動物プロバイオティク・ビフィドバクテリア
EP2261323A1 (de) 2005-05-31 2010-12-15 The Iams Company Probiotische Katzen-Laktobazillen
US8246946B2 (en) 2005-09-27 2012-08-21 Cobb & Associates Treatment of bipolar disorder utilizing anti-fungal compositions
WO2008093303A2 (en) 2007-02-01 2008-08-07 The Iams Company Method for decreasing inflammation and stress in a mammal using glucose antimetaboltes, avocado or avocado extracts
US8825503B2 (en) * 2008-05-15 2014-09-02 Youdocs, Llc Methods and systems for improving human health using targeted probiotics
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
CA2807242C (en) 2010-08-04 2017-05-02 Thomas Julius Borody Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
BR112013022927A2 (pt) 2011-03-09 2016-12-06 Univ Minnesota composição, métodos para substituir ou suplementar ou modificar uma microbiota do cólon de um sujeito, e para tratar um sujeito, e, uso de uma composição
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
US9719144B2 (en) 2012-05-25 2017-08-01 Arizona Board Of Regents Microbiome markers and therapies for autism spectrum disorders
EP2925332A4 (de) 2012-08-20 2016-12-21 Boris Markosian Plazentale impftherapie gegen krebs
CN103060224B (zh) * 2012-09-26 2015-03-18 中国人民解放军总医院 一种空间屎肠球菌lct-ef258菌株
ES2715400T3 (es) 2013-02-05 2019-06-04 Ludwig Stocker Hofpfisterei Gmbh Uso de microorganismos para la prevención y el tratamiento de enfermedades intestinales
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
KR101737332B1 (ko) 2014-11-24 2017-05-18 고려대학교 산학협력단 신규한 엔테로코커스 페시움 l11 균주 및 이를 유효성분으로 포함하는 생균제 조성물
MX383245B (es) 2014-12-05 2025-03-13 Synlogic Operating Co Inc Bacterias modificadas para tratar enfermedades asociadas con hiperamonemia.
CN107208044B (zh) 2014-12-05 2021-08-13 同生运营公司 被工程化为治疗与高氨血症相关的疾病的细菌
US9688967B2 (en) 2014-12-05 2017-06-27 Synlogic, Inc. Bacteria engineered to treat diseases associated with hyperammonemia
KR101702945B1 (ko) 2014-12-17 2017-02-06 삼성중공업 주식회사 분산 제어 시스템 및 그 제어 방법
US20160206666A1 (en) 2014-12-22 2016-07-21 Synlogic, Inc. Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tighten gut mucosal barrier
PE20171138A1 (es) 2014-12-23 2017-08-09 4D Pharma Res Ltd Modulacion inmunitaria
DK3193901T3 (en) 2014-12-23 2018-05-28 4D Pharma Res Ltd PIRIN POLYPEPTIDE AND IMMUNMODULATION
KR20170121291A (ko) 2015-03-02 2017-11-01 신로직 인코포레이티드 감소된 창자 염증 및/또는 강화된 창자 점막 장벽으로부터 이익을 얻는 질병을 치료하기 위해 공학처리된 박테리아
EP3882259B1 (de) 2015-05-13 2026-01-28 Synlogic Operating Company, Inc. Zur reduzierung von hyperphenylalaninämie manipulierte bakterien
EP3294757B1 (de) 2015-05-13 2023-12-27 Synlogic Operating Company, Inc. Manipulierte bakterien zur behandlung einer krankheit oder einer störung
CN114159476A (zh) 2015-05-14 2022-03-11 克雷斯顿沃控股公司 用于粪便菌群移植的组合物以及用于制备和使用它们的方法和用于递送它们的装置
CN114366759A (zh) 2015-05-22 2022-04-19 亚利桑那大学董事会 用于治疗自闭症谱系障碍及相关症状的方法
AU2016274311A1 (en) 2015-06-10 2018-01-18 Synlogic Operating Company, Inc. Bacteria engineered to treat diseases associated with hyperammonemia
PE20180243A1 (es) 2015-06-15 2018-01-31 4D Pharma Res Ltd Composiciones que comprenden cepas bacterianas
EP3662917A1 (de) 2015-06-15 2020-06-10 4D Pharma Research Limited Zusammensetzungen mit bakterienstämmen
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
LT3360559T (lt) 2015-06-15 2019-12-27 4D Pharma Research Limited Kompozicijos, apimančios bakterijų kamienus
WO2016210373A2 (en) 2015-06-24 2016-12-29 Synlogic, Inc. Recombinant bacteria engineered for biosafety, pharmaceutical compositions, and methods of use thereof
WO2016210384A2 (en) 2015-06-25 2016-12-29 Synlogic, Inc. Bacteria engineered to treat metabolic diseases
WO2016210378A2 (en) 2015-06-25 2016-12-29 Synlogic, Inc. Multi-layered control of gene expression in genetically engineered bacteria
EP3328988A1 (de) 2015-07-31 2018-06-06 Synlogic, Inc. Manipulierte bakterien zur behandlung von erkrankungen mit propionatkatabolismus
WO2017040719A1 (en) 2015-08-31 2017-03-09 Synlogic, Inc. Bacteria engineered to treat disorders in which oxalate is detrimental
WO2017074566A1 (en) 2015-10-30 2017-05-04 Dean Falb Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier
US11685925B2 (en) 2015-10-30 2023-06-27 Synlogic Operating Company, Inc. Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier
WO2017075485A1 (en) 2015-10-30 2017-05-04 Synlogic, Inc. Bacteria engineered to treat disorders in which trimethylamine (tma) is detrimental
JP6993970B2 (ja) 2015-11-16 2022-02-15 シンロジック オペレーティング カンパニー インコーポレイテッド 高フェニルアラニン血症を低減させるように操作された細菌
MA41013A (fr) 2015-11-20 2017-08-30 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
GB201520497D0 (en) * 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
WO2017123592A1 (en) 2016-01-11 2017-07-20 Synlogic, Inc. Bacteria engineered to treat disorders associated with bile salts
WO2017123676A1 (en) 2016-01-11 2017-07-20 Synlogic, Inc. Recombinant bacteria engineered to treat diseases and disorders associated with amino acid metabolism and methods of use thereof
WO2017123675A1 (en) 2016-01-11 2017-07-20 Synlogic, Inc. Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
WO2017123610A2 (en) 2016-01-11 2017-07-20 Synlogic, Inc. Bacteria engineered to detoxify deleterious molecules
EP3402497A1 (de) 2016-01-11 2018-11-21 Synlogic Operating Company, Inc. Zur behandlung von stoffwechselerkrankungen manipulierte bakterien
WO2017136792A2 (en) 2016-02-04 2017-08-10 Synlogic, Inc. Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier
WO2017136795A1 (en) 2016-02-04 2017-08-10 Synlogic, Inc. Bacteria engineered to treat diseases associated with tryptophan metabolism
WO2017139708A1 (en) 2016-02-10 2017-08-17 Synlogic, Inc. Bacteria engineered to treat nonalcoholic steatohepatitis (nash)
WO2017139697A1 (en) 2016-02-10 2017-08-17 Synlogic, Inc. Bacteria engineered to treat diseases associated with hyperammonemia
MX373290B (es) 2016-03-04 2020-06-18 4D Pharma Plc Composiciones que comprenden cepas bacterianas.
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
US20170360848A1 (en) 2016-06-15 2017-12-21 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
US10849936B2 (en) 2016-07-01 2020-12-01 Regents Of The University Of Minnesota Compositions and methods for C. difficile treatment
TWI802545B (zh) 2016-07-13 2023-05-21 英商4D製藥有限公司 包含細菌菌株之組合物
US20180036352A1 (en) 2016-08-03 2018-02-08 Crestovo Holdings Llc Methods for treating ulcerative colitis
WO2018071536A1 (en) 2016-10-11 2018-04-19 Crestovo Holdings Llc Compositions and methods for treating primary sclerosing cholangitis and related disorders
WO2018071537A1 (en) 2016-10-11 2018-04-19 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
US10092601B2 (en) 2016-10-11 2018-10-09 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
MX2019008196A (es) 2017-01-06 2019-12-16 Synlogic Operating Co Inc Microorganismos programados para producir moduladores inmunes y productos terapéuticos anti-cáncer en células tumorales.
PL3582808T3 (pl) 2017-02-15 2024-05-20 The Medical College Of Wisconsin, Inc. Zmodyfikowany szczep bakteryjny, który ogranicza kolonizację enterokoków opornych na antybiotyki w przewodzie pokarmowym
WO2018187464A1 (en) 2017-04-05 2018-10-11 Crestovo Holdings Llc Compositions and methods for treating diverticulitis and related disorders
EP3606541A1 (de) 2017-04-05 2020-02-12 Crestovo Holdings LLC Zusammensetzungen und verfahren zur behandlung der parkinson-krankheit (pd) und verwandten erkrankungen
MA48940A (fr) 2017-05-22 2020-04-08 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
MA41708A (fr) 2017-05-24 2020-04-08 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
CN110996917A (zh) 2017-05-26 2020-04-10 克雷斯顿沃控股公司 包含基于粪便微生物的治疗剂的冻干组合物及其制造和使用方法
TWI767013B (zh) 2017-06-14 2022-06-11 英商4D製藥研究有限公司 包含細菌品系之組成物
PL3638271T3 (pl) 2017-06-14 2021-03-22 4D Pharma Research Limited Kompozycje zawierające szczepy bakteryjne
JP2020523326A (ja) 2017-06-14 2020-08-06 フォーディー ファーマ リサーチ リミテッド4D Pharma Research Limited 細菌株を含む組成物
US10941433B2 (en) 2017-06-15 2021-03-09 Iowa State University Research Foundation, Inc. Neurotransmitter transport in probiotics
EP3642221A1 (de) 2017-06-21 2020-04-29 Synlogic Operating Company, Inc. Bakterien zur behandlung von erkrankungen
AU2018301668A1 (en) 2017-07-12 2019-12-19 Synlogic Operating Company, Inc. Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
KR20200038506A (ko) 2017-08-07 2020-04-13 핀치 테라퓨틱스, 인코포레이티드 건강한 장 장벽을 유지 및 회복시키기 위한 조성물 및 방법
BR112020002212A2 (pt) * 2017-08-10 2020-07-28 4D Pharma Research Limited composições compreendendo cepas bacterianas
US20210130806A1 (en) 2017-11-03 2021-05-06 Synlogic Operating Company, Inc. Engineered bacteria expressing racemase for treating diseases associated with hyperammonemia
US11166990B2 (en) 2018-07-13 2021-11-09 Finch Therapeutics Holdings Llc Methods and compositions for treating ulcerative colitis
CN113164527A (zh) 2018-09-27 2021-07-23 芬奇治疗控股有限责任公司 用于治疗癫痫和相关障碍的组合物和方法
KR20220003030A (ko) 2019-04-29 2022-01-07 신로직 오퍼레이팅 컴퍼니, 인코포레이티드 살아 있는 세포 계수 기술에 의한 유전적으로 조작된 미생물의 계수
KR102149185B1 (ko) * 2019-05-09 2020-08-28 한국 한의학 연구원 면역기능 조절 및 염증성 장질환의 개선효과를 갖는 엔테로코쿠스 락티스 WiKim0107 균주 및 이의 용도
WO2021016081A1 (en) 2019-07-19 2021-01-28 Finch Therapeutics Holdings Llc. Methods and products for treatment of gastrointestinal disorders
AU2020354581A1 (en) 2019-09-24 2022-03-03 Prolacta Bioscience, Inc. Compositions and methods for treatment of inflammatory and immune diseases
MX2022007925A (es) 2019-12-24 2022-09-29 Univ Iowa State Res Found Inc Control de histamina para promover la salud y controlar la enterocolitis usando composiciones probioticas y/o enzimas, que degrada histamina.
WO2021188819A1 (en) 2020-03-20 2021-09-23 Synlogic Operating Company, Inc. Microorganisms engineered to reduce hyperphenylalaninemia
CA3188645A1 (en) 2020-08-14 2022-02-17 Prolacta Bioscience, Inc. Human milk oligosaccharide compositions for use with bacteriotherapies
AU2021393455A1 (en) 2020-12-02 2023-06-29 Synlogic Operating Company, Inc. Engineered microorganisms
WO2022146718A1 (en) 2020-12-31 2022-07-07 Synlogic Operating Company, Inc. Microorganisms engineered to reduce hyperphenylalaninemia
MX2023008227A (es) 2021-01-12 2023-07-20 Prolacta Bioscience Inc Regimenes de tratamiento simbiotico.
EP4323385A1 (de) 2021-04-13 2024-02-21 Synlogic Operating Company, Inc. Zur ausscheidung aktiver proteine manipulierte bakterien
RU2766765C1 (ru) * 2021-05-25 2022-03-15 Федеральное государственное бюджетное учреждение "Детский научно-клинический центр инфекционных болезней Федерального медико-биологического агентства" Способ лечения функциональных заболеваний желудочно-кишечного тракта у детей
WO2023044479A1 (en) 2021-09-17 2023-03-23 Synlogic Operating Company, Inc. Methods for reducing hyperphenylalaninemia
EP4405509A4 (de) * 2021-09-20 2025-10-22 Hudson Inst Med Res Biotherapeutische enterococcus isolate
WO2023245168A1 (en) 2022-06-17 2023-12-21 Synlogic Operating Company, Inc. Bacteria engineered to treat diseases associated with bile acid metabolism and methods of use thereof
WO2023245171A1 (en) 2022-06-17 2023-12-21 Synlogic Operating Company, Inc. Bacteria engineered to treat diseases associated with bile acid metabolism and methods of use thereof
US20230414679A1 (en) 2022-06-22 2023-12-28 Iowa State University Research Foundation, Inc. Control of histamine to promote health and control enterocolitis using probiotic compositions
US20260199405A1 (en) 2022-06-23 2026-07-16 Synlogic Operating Company, Inc. Recombinant bacteria engineered to treat diseases associated with methionine metabolism and methods of use thereof
WO2024081768A1 (en) 2022-10-12 2024-04-18 Synlogic Operating Company, Inc. Bacteria engineered to produce active epidermal growth factor (egf) and their medical uses
JP2025534764A (ja) 2022-10-17 2025-10-17 シンロジック オペレーティング カンパニー インコーポレイテッド 高フェニルアラニン血症を軽減するためのフェニルアラニンアンモニアリアーゼ、フェニルアラニントランスポーターおよびl-アミノ酸デアミナーゼを発現する組み換え細菌
WO2024129974A1 (en) 2022-12-14 2024-06-20 Synlogic Operating Company, Inc. Recombinant bacteria for use in the treatment of disorders in which oxalate is detrimental
WO2024130119A2 (en) 2022-12-16 2024-06-20 Prolacta Bioscience, Inc. Synbiotic compositions for short chain fatty acid production
EP4647439A1 (de) 2024-05-09 2025-11-12 Alma Mater Studiorum - Università di Bologna Nicht pathogene bakterien zur verabreichung von ptd-fusionsproteinen

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1771677B2 (de) * 1968-06-25 1972-09-07 Hoesch Ag, 4600 Dortmund Verfahren und vorrichtung zur aufbringung einer emailaehnlichen, gegebenfalls ein korrosionsschutzmittel enthaltenden ueberzugsschicht als korrosionsschutzschicht auf metallisches walzgut
JPS5927833A (ja) * 1982-08-06 1984-02-14 Advance Res & Dev Co Ltd コレステロール乃至トリグリセリド低下剤
JPS615022A (ja) * 1984-06-19 1986-01-10 Advance Res & Dev Co Ltd 腸内細菌叢改善剤
DE3509239A1 (de) * 1985-03-14 1986-09-18 Angelo 8137 Berg Schuler Diaetetisches mittel
SE8702435L (sv) * 1987-06-11 1988-12-12 Medipharm Ab Saett att oeka proteinhalten i mjoelk hos mjoelkproducerande djur
JPS6483025A (en) * 1987-09-24 1989-03-28 Fujio Hayashi Blended preparation of drug-resistant live bacterium agent for controlling intestinal function and antibacterial agent
AU640349B2 (en) * 1988-08-02 1993-08-26 Borody, Thomas J Dr Treatment of gastro-intestinal disorders
US5116737A (en) * 1989-03-14 1992-05-26 Chr. Hansen's Laboratory, Inc. Method for growing acid-producing bacteria
US5292657A (en) * 1990-12-31 1994-03-08 Pioneer Hi-Bred International, Inc. Process for preparing rotary disc fatty acid microspheres of microorganisms
US5501857A (en) * 1992-07-24 1996-03-26 Midwestern Bio-Ag Products & Services, Inc. Oral nutritional and dietary composition
US5340577A (en) * 1992-07-29 1994-08-23 The United States Of America, As Represented By The Secretary Of Agriculture Probiotic for control of salmonella
US5478557A (en) * 1992-07-29 1995-12-26 The United States Of America, As Represented By The Secretary Of Agriculture Probiotic for control of salmonella

Also Published As

Publication number Publication date
AU1473892A (en) 1992-10-15
ES2089398T3 (es) 1996-10-01
GR3021069T3 (en) 1996-12-31
JP3186202B2 (ja) 2001-07-11
NZ242195A (en) 1995-04-27
EP0508701A3 (en) 1993-05-05
DE69212034T2 (de) 1997-01-23
US5589168A (en) 1996-12-31
GB9107305D0 (en) 1991-05-22
DK0508701T3 (da) 1996-10-28
DE69212034D1 (de) 1996-08-14
JPH05252934A (ja) 1993-10-05
US5728380A (en) 1998-03-17
CA2064954A1 (en) 1992-10-09
IE921092A1 (en) 1992-10-21
EP0508701B1 (de) 1996-07-10
AU652815B2 (en) 1994-09-08
KR920019930A (ko) 1992-11-20
EP0508701A2 (de) 1992-10-14
KR0123456B1 (ko) 1997-11-19

Similar Documents

Publication Publication Date Title
AU652815B2 (en) Probiotic
TR200102058T2 (tr) Lactobacillus salivarius'un kullanımı
MXPA04000808A (es) Cepas probioticas de lactobacillus salivarius.
DE69919518D1 (de) Lactobacillus-stamm
FI20012509L (fi) Uudet Lactobacillus-kannat ja niiden käyttö elintarvikkeiden, erityisesti kauravellin valmistamiseen
EA200101262A1 (ru) Диетическая или фармацевтическая композиция для применения в целях профилактики или лечения гипероксалурии
BR0211442A (pt) Cepas de bifidobacterium probióticas
CA2321263A1 (en) Use of bacteria endowed with arginine deiminase to induce apoptosis and/or reduce an inflammatory reaction and pharmaceutical or dietetic compositions containing such bacteria
BR9608284A (pt) Composição farmacêutica compreendendo lactobacillus plantarum e arginina
EP0257189A3 (en) Novel bacillus brevis strains and application thereof
Turner et al. Informal support of people with AIDS: Issues of age, stress, & caregiving.
EE05412B1 (et) Bifidobacterium'i perekonna probiootiliste tvede skriinimise meetod
JPS6455156A (en) 'natto'
IT1269838B (it) Ceppi di lattobacilli di origine umana e loro usi
LV5677A3 (lv) Bakteriju lactobacillus casei var. alactosus celms - L(+)-pienskabes producents izmantojams lopbaribas konservesanai
JPS642570A (en) Bacillus subtilis strain and elimination of aflatoxin contamination using said strain
KR900013912A (ko) 신비의 맥반석 도자기 구이판
Postovit et al. Specific immunological features observed in patients of different age groups in typhoid fever and their importance for the clinical manifestations of the disease.
Qiu The capacity of IL-2 production of peripheral blood lymphocyte in patients with pneumonia
Adam et al. Rational use of oral antibiotics in medical practice.
MD669F1 (ro) Tulpina a bacteriilor Lactobacillus Acidophilus utilizata la prepararea eubioticelor The bacteria strain Lactobacillus acidophilus used for eubiotics preparation
ITMO910048V0 (it) Dispositivo per rilevare il distacco del tampone in presse ceramiche e simili
RO101499A2 (ro) Compozitie de cauciuc pentru articole tehnice extrudate

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee